A study of an experimental drug for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new investigational medicine for prostate cancer that has spread and is no longer controlled by standard hormone therapy. The drug may work by targeting a protein on cancer cells, and the trial will check if it can shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult male, at least 18 years old.
- Your prostate cancer has spread and is still growing despite treatment with hormone therapy (like abiraterone or enzalutamide).
- You are generally well enough to care for yourself and are not bedridden.
- Your cancer is of a common type (adenocarcinoma), not a rare small-cell type.
- You have not previously treated with a specific type of drug called an antibody-drug conjugate (ADC) or with a topoisomerase I inhibitor (like irinotecan).
- You do not have significant heart, lung, or liver disease, and no recent other cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called QLF4113 for men with metastatic castration-resistant prostate cancer (mCRPC) that has not responded to standard treatments. The goal is to see if QLF4113 can help control the cancer.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new drug called QLS2401 for patients with advanced prostate cancer that has spread and no longer responds to standard treatments. The goal is to see if it can help control the cancer.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.